The role of catechol-O-methyl-transferase (COMT) inhibitors in the treatment of late complications of Parkinson's disease - Effectiveness and safety of entacapone (Comtan®)

Ceska a Slovenska Neurologie a Neurochirurgie

Volumn 65, Issue 2, 2002, Pages 69-75

  Bares M ^a   Kanovsky B ^a   Rektor, I ^a  

^a UNIVERSITY HOSPITAL BRNO   (Czech Republic)

Author keywords

COMT inhibitors; Entacapone; Long term evaluation; Parkinson's disease; Safety

Indexed keywords

AMANTADINE; AMINOTRANSFERASE; ANTIPARKINSON AGENT; BENSERAZIDE PLUS LEVODOPA; BIPERIDEN; CARBIDOPA PLUS LEVODOPA; CATECHOL METHYLTRANSFERASE INHIBITOR; DOPAMINE RECEPTOR STIMULATING AGENT; ENTACAPONE; LEVODOPA; LIVER ENZYME; SELEGILINE; TOLCAPONE;

ADULT; AGED; ARTICLE; BLOOD ANALYSIS; CEREBROVASCULAR ACCIDENT; COGNITIVE DEFECT; CONTROLLED STUDY; DIARRHEA; DISEASE DURATION; DRUG EFFICACY; DRUG FORMULATION; DRUG HYPERSENSITIVITY; DRUG RESPONSE; DRUG SAFETY; DYSKINESIA; DYSPEPSIA; FEMALE; FOLLOW UP; FUNCTIONAL ASSESSMENT; HALLUCINATION; HEART FAILURE; HUMAN; LABORATORY TEST; MAJOR CLINICAL STUDY; MALE; MORTALITY; MOTOR PERFORMANCE; NEUROLOGIC EXAMINATION; ONSET AGE; ORTHOSTATIC HYPOTENSION; PARKINSON DISEASE; PATIENT COMPLIANCE; SCORING SYSTEM; STATISTICAL ANALYSIS; WAKEFULNESS;

EID: 0036210343     PISSN: 12107859     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. Pharmacokinetics of levodopa
2. The metabolism of L-3-O-methyldopa, a precursor of dopa in man
3. Catechol-O-methyltransferase: Pharmacological aspects and physiological role
4. Ro 40-7592, a COMT inhibitor, plus levodopa in Parkinson's disease
5. Acute administration of levodopa-benserazide and tolcapone, a COMT inhibitor, in Parkinson's disease
6. Tolcapone in stable Parkinson's disease efficacy and safety of long term treatment
7. Efficacy and safety of tolcapone in levodopa-treated Parkinson's disease patients with "wearing-off" phenomenon. A multicenter, double-blind, randomized placebo-controlled trial
8. Tolcapone and fulminant hepatitis
9. Effect of entacapone, a peripherally acting catecho-O-methyltransferase inhibitor, on the motor response to acute levodopa in patients with Parkinson's disease
10. Effect of entacapone, a COMT inhibitor, on clinical disability and levodopa metabolism in parkinsonian patients
11. Entacapone enhances the response to levodopa in parkinsonian patients with motor fluctuations
12. Unified Parkinson's disease rating scale
13. Pharmacokinetics of oral entacapone after frequent multiple dosing and effects on levodopa disposition
14. Effect of peripheral catechol-O-methyltransferase inhibition on the pharmacokinetics and pharmacodynamics of levodopa in parkinsonian patients
15. The COMT-inhibitor entacapone increases "on" time in levodopa-treated PD patients with motor fluctuations: Report of two randomized, placebo-controlled trials
16. Entacapone prolongs levodopa response in a one month double blind study in parkinsonian patients with levodopa related fluctuations
17. The catechol-O-methyltransferase (COMT) inhibitor entacapone enhances the pharmacokinetic and clinical response to Sinement CR in Parkinson's disease
18. Perspectives in the treatment of Parkinson's disease: COMT inhibitors open up new treatment strategies
19. Catechol-O-methyltransferase inhibitors: Clinical potential in the treatment of Parkinson's disease
20. Catechol-O-methyltransferase (COMT): Biochemistry, molecular biology, pharmacology, and clinical efficacy of the new selective COMT inhibitors
21. Entacapone, a catechol-O-methyltransferase inhibitor for treating Parkinson's disease: Review and current status
22. COMT inhibition with entacapone in the treatment of Parkinson's disease
23. New, selective catechol-O-methyltransferase inhibitors as therapeutic agents in Parkinson's disease
24. Twelve-month safety of entacapone in patients with Parkinson's disease